EP4121105A4 - Vaccines formed by virus and antigen conjugation - Google Patents

Vaccines formed by virus and antigen conjugation Download PDF

Info

Publication number
EP4121105A4
EP4121105A4 EP21793816.6A EP21793816A EP4121105A4 EP 4121105 A4 EP4121105 A4 EP 4121105A4 EP 21793816 A EP21793816 A EP 21793816A EP 4121105 A4 EP4121105 A4 EP 4121105A4
Authority
EP
European Patent Office
Prior art keywords
virus
antigen conjugation
vaccines
vaccines formed
conjugation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21793816.6A
Other languages
German (de)
French (fr)
Other versions
EP4121105A1 (en
Inventor
Steven D. Hume
Leigh Burden
Joshua Morton
Greg POGUE
Barry Bratcher
Hugh A. Haydon
Carrie A. Simpson
Nick Partain
Youngjun Oh
John W. Shepherd
Michael H. Pauly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kbio Holdings Ltd
Original Assignee
Kbio Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/919,943 external-priority patent/US11696948B2/en
Priority claimed from US17/186,941 external-priority patent/US11690907B2/en
Application filed by Kbio Holdings Ltd filed Critical Kbio Holdings Ltd
Publication of EP4121105A1 publication Critical patent/EP4121105A1/en
Publication of EP4121105A4 publication Critical patent/EP4121105A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21793816.6A 2020-04-21 2021-03-05 Vaccines formed by virus and antigen conjugation Pending EP4121105A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063013284P 2020-04-21 2020-04-21
US202063047629P 2020-07-02 2020-07-02
US16/919,943 US11696948B2 (en) 2018-06-12 2020-07-02 Vaccines formed by virus and antigen conjugation
US17/186,941 US11690907B2 (en) 2018-06-12 2021-02-26 Vaccines formed by virus and antigen conjugation
PCT/US2021/021087 WO2021216205A1 (en) 2020-04-21 2021-03-05 Vaccines formed by virus and antigen conjugation

Publications (2)

Publication Number Publication Date
EP4121105A1 EP4121105A1 (en) 2023-01-25
EP4121105A4 true EP4121105A4 (en) 2024-05-15

Family

ID=78270938

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21793816.6A Pending EP4121105A4 (en) 2020-04-21 2021-03-05 Vaccines formed by virus and antigen conjugation

Country Status (3)

Country Link
EP (1) EP4121105A4 (en)
JP (1) JP2023523716A (en)
WO (1) WO2021216205A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116789847B (en) * 2023-01-13 2024-04-16 广州医科大学附属第一医院（广州呼吸中心） Fusion proteins, virus-like particles and vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097851A2 (en) * 2005-03-17 2006-09-21 Novartis Vaccines And Diagnostics Srl Combination vaccines with whole cell pertussis antigen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20130280298A1 (en) * 2006-11-15 2013-10-24 Folia Biotech Inc. Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof
US9889194B2 (en) * 2013-03-01 2018-02-13 New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
JP7315590B2 (en) * 2018-06-12 2023-07-26 クビオ・ホールディングス・リミテッド Purification and binding of viruses and antigens
KR102076917B1 (en) * 2018-10-25 2020-02-13 연세대학교 산학협력단 Expression vector system for preparing recombinant self-assembled nanoparticles, and method of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097851A2 (en) * 2005-03-17 2006-09-21 Novartis Vaccines And Diagnostics Srl Combination vaccines with whole cell pertussis antigen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GASANOVA T V ET AL: "Chimeric particles of tobacco mosaic virus as a platform for the development of next-generation nanovaccines", NANOTECHNOLOGIES IN RUSSIA, MAIK NAUKA - INTERPERIODICA, RU, vol. 11, no. 3-4, 1 March 2016 (2016-03-01), pages 227 - 236, XP037125224, ISSN: 1995-0780, [retrieved on 20160513], DOI: 10.1134/S1995078016020051 *
GASANOVA T V ET AL: "Complexes Formed via Bioconjugation of Genetically Modified TMV Particles with Conserved Influenza Antigen: Synthesis and Characterization", BIOCHEMISTRY (MOSCOW), PLEIADES PUBLISHING, MOSCOW, vol. 85, no. 2, 1 February 2020 (2020-02-01), pages 224 - 233, XP037023469, ISSN: 0006-2979, [retrieved on 20200217], DOI: 10.1134/S0006297920020091 *
PETUKHOVA NATALIA ET AL: "High-Level Systemic Expression of Conserved Influenza Epitope in Plants on the Surface of Rod-Shaped Chimeric Particles", VIRUSES, vol. 6, no. 4, 21 April 2014 (2014-04-21), CH, pages 1789 - 1800, XP093142307, ISSN: 1999-4915, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014720/pdf/viruses-06-01789.pdf> DOI: 10.3390/v6041789 *
PETUKHOVA NATALIA ET AL: "Immunogenicity and Protective Efficacy of Candidate Universal Influenza A Nanovaccines Produced in Plants by Tobacco Mosaic Virus-based Vectors", CURRENT PHARMACEUTICAL DESIGN, vol. 19, no. 31, 1 August 2013 (2013-08-01), NL, pages 5587 - 5600, XP093142312, ISSN: 1381-6128, DOI: 10.2174/13816128113199990337 *
See also references of WO2021216205A1 *
SMITH M L ET AL: "Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 348, no. 2, 10 May 2006 (2006-05-10), pages 475 - 488, XP024896651, ISSN: 0042-6822, [retrieved on 20060510], DOI: 10.1016/J.VIROL.2005.12.039 *

Also Published As

Publication number Publication date
WO2021216205A1 (en) 2021-10-28
CN115996750A (en) 2023-04-21
JP2023523716A (en) 2023-06-07
EP4121105A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
EP3806629A4 (en) Virus and antigen purification and conjugation
EP3958910A4 (en) Anti-cd45 antibody drug conjugates and uses thereof
WO2006041933A3 (en) Improved vaccines
WO2015142671A3 (en) Influenza virus vectors and uses therefor
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2015175355A8 (en) Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates
GB202104898D0 (en) CpG-adjuvanted SARS-CoV-2 virus vaccine
CA2763359C (en) New human rotavirus strains and vaccines
EP4028417A4 (en) Anti-oncolytic virus antigen antibodies and methods of using same
MX2015002483A (en) Immunogenic compositions.
EP3941946A4 (en) Claudin-6 antibodies and drug conjugates
EP3823620A4 (en) Opioid haptens, conjugates, vaccines, and methods of generating antibodies
WO2020157222A8 (en) Inactivated apxia, apxiia and apxiiia toxins
EP3858383A4 (en) Immune inducer comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same
EP4076518A4 (en) Vaccines against african swine fever virus, and methods of using same
WO2019147869A3 (en) Recombinant viral vaccines
EP4125944A4 (en) Infectious disease antigens and vaccines
EP3730620A4 (en) Cross-immunizing antigen vaccine and method for preparation thereof
EP4051711A4 (en) Anti-cd45 antibodies and conjugates thereof
EP3664846A4 (en) Antibody to epstein barr virus and uses thereof
EP4121105A4 (en) Vaccines formed by virus and antigen conjugation
EP3930767A4 (en) Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same
EP3549604A4 (en) Recombinant bivalent inactivated vaccine for foot-and-mouth disease and preparation method and application thereof
WO2007146359A3 (en) Sea lice antigen vaccines

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230620

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085914

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240412

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20240408BHEP

Ipc: A61P 31/16 20060101ALI20240408BHEP

Ipc: A61K 39/12 20060101ALI20240408BHEP

Ipc: A61K 39/145 20060101AFI20240408BHEP